Daniel Doty Email & Phone Number

Arlington, MA, US

Andover, Massachusetts, United States

• Independently planned and executed cytometry assays with biotherapeutic molecules utilizing flow- and imaging flow-cytometry instruments, the FACSymphony A5 and the Amnis ImageStream, respectively
• Developed, adapted and optimized flow- and imaging flow-cytometry assays
• Applied advanced knowledge of multi-parameter flow cytometry to effectively develop and optimize complex cell-based bioanalytical and functional assays
• Critically analyzed experimental data and communicated the results across multiple teams with diverse scientific and technical backgrounds
• Collaborated within and without the group; fostered partnerships in a matrix environment; worked closely with cross-functional teams to plan and execute deliverables and prioritize activities according to project goals
• Adhered to scientific rigor and quality management system standards, including electronic record keeping using ELN, data peer-review, quality control and reporting

Cambridge, MA

• Contributed key design features to a microfluidic platform for modeling tumor-immune interactions
• Collaborated in multidisciplinary teams to complete complex project objectives on tight timelines
• Developed methods and protocols for novel platforms
• Worked on several microfluidic cell processing projects, including electroporation, viral transduction, and acoustic separation
• Coordinated the planning, execution, and analysis of experiments with electrical and mechanical engineers
• Isolated, cultured, and characterized immune cells from primary human tissues

• Characterized and profiled tumor infiltrating lymphocytes on a population level by flow cytometry, and on the single cell level using Enumeral’s proprietary platform
• Successfully led a screening campaign that yielded a patent application for matched heavy and light chain antibody sequences against a specific immuno-modulatory receptor
• Developed cell-based functional assays to compare novel drug candidates with competitors
• Devised and performed screens of primary B cells from autoimmune patients for specific anti-self antibodies
• Devised and performed screens of individual primary human B cells for specific anti-viral antibodies
• Improved overall yield and reliability of Enumeral’s platform through process optimization, developing it from its academic origins to a much more robust, commercially viable technique

• Executed the experiments required for a successful Investigational New Drug (IND) application with the FDA.
• Performed functional characterization of novel monoclonal antibodies that modulate immune function.
• Analyzed the method of action (MOA) of the antibody in vivo using murine tumor models.
• Analyzed the MOA of the antibodies using ex vivo and in vitro cellular immunology studies including flow cytometry, ELISPOT, cell proliferation studies, mixed lymphocyte reaction (MLR), etc.
• Developed and optimized cell-based- and flow cytometry-based assays, ELISAs, and Biacore™ assays.
• Mammalian cell culture, animal handling, and human tissue handling in a BL2 environment.

• Measured in vivo antigen-specific immune response to vaccine candidates with both cell-based and biochemical-based assays (with FACS, ELISA, ELISPOT, viral plaque assays, etc.).
• Developed and optimized cell- and flow cytometry-based assays.
• Conducted clinical trial experiments using Good Laboratory Practices.
• Collaborated in a wide variety of multidisciplinary, team-based projects.
• Virology, mammalian cell culture, and animal handling in a BL2 environment.
• Laboratory Safety Committee member representing the Immunology group.

M.S., Biology

B.S., Molecular And Cell Biology

Activities and Societies: Phi Beta KappaSumma Cum Laude and Honors